{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":null,"prefName":"Cannabidivarina","symbol":"CBDV","iupacName":null,"aliases":["Cannabidivarine"],"cas":"24274-48-4","pubchemCid":"11601669","chebiId":null,"smiles":"CCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O","molecularFormula":"C19H26O2","molecularWeight":null,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/11601669"}},"classification":{"family":"mineur","familyLabel":"Fitocannabinoide menor","origin":"natural","originLabel":"Naturel","structuralClassFr":null},"originSynthesis":{"heading":"Vía biosintética","summaryFr":"Versión propílica del CBD - cadena propilo en lugar de pentilo - rama varínica de la vía CBGVA","originNote":"Planta","discovered":"1969"},"pharmacology":{"summaryFr":"Como el THCV es al THC, el CBDV es al CBD: versión propílica, sin afinidad CB1 significativa y, por tanto, sin efecto psicotrópico. Varios ensayos clínicos de fase II lo evalúan como molécula candidata en la epilepsia farmacorresistente (programas de GW Pharmaceuticals, retomados desde entonces por Jazz Pharmaceuticals) y en algunos trastornos del espectro autista, donde parece modular la excitabilidad neuronal a través de los canales TRPV1. Perfil de tolerabilidad próximo al del CBD, con un efecto antinauseoso a veces más marcado según los estudios preclínicos. Presencia rara en los quimiotipos comerciales europeos - cuando se ofrece, está documentado lote a lote.","receptorSummaryFr":"Modulador de TRPV1 (canales vaniloides), inhibidor de la DAGL-α, sin afinidad CB1 significativa","binding":[{"target":"TRPV1","efficacy":"modulator","relativeActivity":60,"reported":null,"confidence":"low"},{"target":"DAGL-α","efficacy":"antagonist","relativeActivity":50,"reported":null,"confidence":"low"},{"target":"CB1","efficacy":"partial_agonist","relativeActivity":10,"reported":null,"confidence":"low"}],"references":[]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calma","description":"Relajación del cuerpo y de la mente; menos ruido mental, sin somnolencia marcada.","intensity":75},{"key":"focus","label":"Claridad","description":"Atención sostenida y pensamiento claro; lucidez funcional, sin euforia.","intensity":60},{"key":"sleep","label":"Sueño","description":"Efecto sedante: favorece la conciliación del sueño y la continuidad del sueño profundo.","intensity":50},{"key":"appetite","label":"Apetito","description":"Estimulación del hambre y de la apreciación gustativa (efecto «munchies»).","intensity":20},{"key":"uplift","label":"High","description":"Euforia e intensidad sensorial; percepción del tiempo y del espacio modificada.","intensity":35}],"doseRanges":null,"humanDataCharacterised":true},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":false,"bannerTextFr":null,"toxicologyFr":null},"legal":{"scheduleStatus":"industrial-exempt","scheduleLabel":"Excepción del cáñamo","frScheduleStatus":null,"tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"Autorizado","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Autorizado","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[],"meta":{"slug":"cbdv","url":"https://es.phytogrammes.com/wiki/cbdv","lastVerified":"2026-05-01","dataUpdatedAt":"2026-05-01","confidence":"low","dataCompletenessPct":70,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}